AstraZeneca reports positive results in latest lung cancer trials
Sharecast
Published May 17, 2023 10:53
AstraZeneca reports positive results in latest lung cancer trials
Sharecast - The FTSE 100 pharmaceuticals giant said the combination had the potential to significantly improve progression-free survival (PFS) in patients with locally-advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
It said the trial indicated that Tagrisso and chemotherapy resulted in a statistically-significant and clinically-meaningful improvement in PFS when compared to Tagrisso alone.
The study specifically focussed on patients with stage 3b to 3c, and stage four, NSCLC.
While the overall survival data was still considered immature at the time of analysis, they would undergo further evaluation in subsequent assessments.
Looking at safety, the trial demonstrated that the combination treatment had consistent safety profiles and discontinuation rates due to adverse events, aligning with the established records of each medicine involved.
“These significant FLAURA2 results show Tagrisso has the potential to offer patients in the first-line setting a new treatment option that can extend the time they live without their disease progressing,” said AstraZeneca’s executive vice-president of oncology research and development, Susan Galbraith.
“This meaningfully builds on successive trials which have demonstrated improved clinical benefit with Tagrisso in patients with EGFR-mutated lung cancer.”
At 0953 BST, shares in AstraZeneca PLC (LON:AZN) were up 0.85% at 12,168p.
Reporting by Josh White for Sharecast.com.
Read more on Sharecast.com
Get The App
Written By: Sharecast
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.